Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation

Tracy Criswell, Konstantin Leskov, Shigeki Miyamoto, Guangbin Luo, David A. Boothman

Research output: Contribution to journalArticle

193 Citations (Scopus)

Abstract

Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (≤2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-κB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.

Original languageEnglish (US)
Pages (from-to)5813-5827
Number of pages15
JournalOncogene
Volume22
Issue number37 REV. ISS. 3
DOIs
StatePublished - Sep 1 2003

Fingerprint

Ionizing Radiation
Transcription Factors
Proteins
Retinoblastoma Protein
NF-kappa B
Radio
Signal Transduction
Research Personnel

Keywords

  • DNA damage sensors
  • Ionizing radiation (IR)
  • NF-κB
  • p53
  • Signal transduction
  • SP1

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Criswell, T., Leskov, K., Miyamoto, S., Luo, G., & Boothman, D. A. (2003). Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene, 22(37 REV. ISS. 3), 5813-5827. https://doi.org/10.1038/sj.onc.1206680

Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. / Criswell, Tracy; Leskov, Konstantin; Miyamoto, Shigeki; Luo, Guangbin; Boothman, David A.

In: Oncogene, Vol. 22, No. 37 REV. ISS. 3, 01.09.2003, p. 5813-5827.

Research output: Contribution to journalArticle

Criswell, T, Leskov, K, Miyamoto, S, Luo, G & Boothman, DA 2003, 'Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation', Oncogene, vol. 22, no. 37 REV. ISS. 3, pp. 5813-5827. https://doi.org/10.1038/sj.onc.1206680
Criswell, Tracy ; Leskov, Konstantin ; Miyamoto, Shigeki ; Luo, Guangbin ; Boothman, David A. / Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. In: Oncogene. 2003 ; Vol. 22, No. 37 REV. ISS. 3. pp. 5813-5827.
@article{a5a9b594ba8f41d4b931867528729355,
title = "Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation",
abstract = "Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (≤2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-κB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.",
keywords = "DNA damage sensors, Ionizing radiation (IR), NF-κB, p53, Signal transduction, SP1",
author = "Tracy Criswell and Konstantin Leskov and Shigeki Miyamoto and Guangbin Luo and Boothman, {David A.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1038/sj.onc.1206680",
language = "English (US)",
volume = "22",
pages = "5813--5827",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "37 REV. ISS. 3",

}

TY - JOUR

T1 - Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation

AU - Criswell, Tracy

AU - Leskov, Konstantin

AU - Miyamoto, Shigeki

AU - Luo, Guangbin

AU - Boothman, David A.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (≤2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-κB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.

AB - Over the past 15 years, a wealth of information has been published on transcripts and proteins 'induced' (requiring new protein synthesis) in mammalian cells after ionizing radiation (IR) exposure. Many of these studies have also attempted to elucidate the transcription factors that are 'activated' (i.e., not requiring de novo synthesis) in specific cells by IR. Unfortunately, all too often this information has been obtained using supralethal doses of IR, with investigators assuming that induction of these proteins, or activation of corresponding transcription factors, can be 'extrapolated' to low-dose IR exposures. This review focuses on what is known at the molecular level about transcription factors induced at clinically relevant (≤2 Gy) doses of IR. A review of the literature demonstrates that extrapolation from high doses of IR to low doses of IR is inaccurate for most transcription factors and most IR-inducible transcripts/proteins, and that induction of transactivating proteins at low doses must be empirically derived. The signal transduction pathways stimulated after high versus low doses of IR, which act to transactivate certain transcription factors in the cell, will be discussed. To date, only three transcription factors appear to be responsive (i.e. activated) after physiological doses (doses wherein cells survive or recover) of IR. These are p53, nuclear factor kappa B(NF-κB), and the SP1-related retinoblastoma control proteins (RCPs). Clearly, more information on transcription factors and proteins induced in mammalian cells at clinically or environmentally relevant doses of IR is needed to understand the role of these stress responses in cancer susceptibility/resistance and radio-sensitivity/resistance mechanisms.

KW - DNA damage sensors

KW - Ionizing radiation (IR)

KW - NF-κB

KW - p53

KW - Signal transduction

KW - SP1

UR - http://www.scopus.com/inward/record.url?scp=0141645610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141645610&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1206680

DO - 10.1038/sj.onc.1206680

M3 - Article

C2 - 12947388

AN - SCOPUS:0141645610

VL - 22

SP - 5813

EP - 5827

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 37 REV. ISS. 3

ER -